Wells Fargo analyst Derek Archila raised the firm’s price target on Kyverna Therapeutics (KYTX) to $31 from $27 and keeps an Overweight rating on the shares. The firm believes KYV-101’s pivotal programs in Myasthenia Gravis and Stiff-Person Syndrome are highly de-risked and remain unappreciated by investors. Wells cites a higher probability of success for MG, and believes shares should work up into the pivotal SPS read out in the first half of 2026.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYTX:
- Kyverna Therapeutics’ KYV-101 Shows Promising Phase II Results in gMG, Supporting Buy Rating
- Kyverna Therapeutics price target raised to $31 from $27 at Wells Fargo
- Kyverna Therapeutics Reports Positive Phase 2/3 Trial Data
- Kyverna Therapeutics Reports Positive Phase 2 Trial Results
- Kyverna Therapeutics announces data from Phase 2 from KYSA-6 clinical trial